<qa>  What is the median overall survival of lurbinectedin?Phase III randomized clinical trial of lurbinectedin PM01183doxorubicin DOX versus cyclophosphamide CTX, doxorubicin DOX and vincristine VCR CAV or topotecan as treatment in patients with small-cell lung cancer SCLC who failed one prior platinum-containing line to determine a difference in progression-free survival PFS by an Independent Review Committee IRC between lurbinectedin PM01183doxorubicin DOX and the control arm CAV or topotecan and to analyze the median overall survival OS and mid- and long-term overall survival OS at 12, 18 and 24 months. 